SCHEMBL1085197

SCHEMBL1085197

CCOC(=O)c1c(C)cc(-c2cccc(OC(F)(F)F)c2)nc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CTSS P25774 1/20 0.47
CTSK P43235 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ADORA3 P0DMS8 4/20 0.47
KDM4E B2RXH2 6/20 0.47
MAPT P10636 4/20 0.47
HPGD P15428 4/20 0.47
RAB9A P51151 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
LMNA P02545 2/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 1/20 0.47
XDH P47989 1/20 0.46
THRB P10828 1/20 0.46
HSD17B10 Q99714 2/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085051 0.87 XDH (0.49) CTSSCTSKXDHHSD17B10TRPV3
SCHEMBL1085386 0.86 ALDH1A1 (0.57) ALDH1A1L3MBTL1SMN1; SMN2ADORA3KDM4E
SCHEMBL1550043 0.76 ALDH1A1 (0.79) ALDH1A1L3MBTL1SMN1; SMN2ADORA3KDM4E
SCHEMBL2777083 0.75 TDP1 (0.53) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL1083727 0.74 L3MBTL3 (0.43) L3MBTL1NPSR1CYP2C9CYP2C19
SCHEMBL1327099 0.74 SMN1; SMN2 (0.51) ALDH1A1L3MBTL1SMN1; SMN2ADORA3KDM4E
SCHEMBL1085587 0.74 ALDH1A1 (0.53) ALDH1A1L3MBTL1SMN1; SMN2ADORA3KDM4E
SCHEMBL27788627 0.73 HSD11B1 (0.40) ALDH1A1SMN1; SMN2KDM4EMAPTHPGD
SCHEMBL3755311 0.73 ALDH1A1 (0.48) ALDH1A1L3MBTL1SMN1; SMN2ADORA3KDM4E
SCHEMBL16398996 0.73 RAB9A (0.53) ALDH1A1L3MBTL1SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
EP-2205583-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 ALDH1A1 1202/4885L3MBTL1 2710/4885CTSS 3130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.